Casein Kinase Inhibitor

Casein Kinase Inhibitors (63):

Cat. No.	Product Name	Effect	Purity

HY-115519

(E/Z)-GO289	Inhibitor	98.98%
(E/Z)-GO289 is a potent and selective casein kinase 2 (CK2) inhibitor (IC₅₀=7 nM). (E/Z)-GO289 strongly lengthens circadian period. (E/Z)-GO289 exhibits cell type–dependent inhibition of cancer cell growth that correlated with cellular clock function.

HY-145939

BAY-888	Inhibitor	98.27%
BAY-888 is a selective CK1α/CSNK1A1 (casein kinase 1α) ATP-competitive inhibitor (IC₅₀: 4 nM@10 μM ATP; 63 nM@1 mM ATP). BAY-888 blocks the negative regulation of p53 and other signaling pathways by CK1α, induces apoptosis and inhibits proliferation of tumor cells. BAY-888 has shown inhibitory efficacy against cancers such as acute myeloid leukemia (AML) in PRISM barcoded cell line screening and can mimic the effects of shRNA-mediated CK1α knockdown. BAY-888 is primarily used for the development of anticancer drugs for p53 wild-type tumors and for the study of the mechanisms of CK1α-related signaling pathways.

HY-174347

Hsp90-Cdc37-IN-4	Inhibitor
Hsp90-Cdc37-IN-4, a Celastrol (HY-13067) derivative, inhibits the Hsp90-Cdc37 protein-protein interaction (PPI). Hsp90-Cdc37-IN-4 selectively inhibits casein kinase 2 (CK2), reducing phosphorylation of its substrate Cdc37 at Serine 13. Hsp90-Cdc37-IN-4 induces G0/G1 cell cycle arrest and triggers apoptosis via the mitochondrial pathway. Hsp90-Cdc37-IN-4 demonstrates potent anti-breast cancer activity.

HY-174371

INNO-220	Inhibitor
INNO-220 is an orally active, CRBN-dependent molecular glue degrader targeting CK1α. INNO-220 induces cell cycle arrest at G0/G1 phase and triggers apoptosis by degrading CK1α. INNO-220 disrupts the assembly and function of the CARD11/BCL10/MALT1 complex, thereby inhibiting NF-κB signaling in stimulated T cells and lymphoma cells that harbor an activating mutation in CARD11. INNO-220 provides a new direction for lymphoma research.

HY-158975

VRK1/CK1-IN-1	Inhibitor	98.69%
VRK1/CK1-IN-1 (compound 36) is a dual inhibitor of vaccinia-related kinase 1 (VRK1) and casein kinase 1 (CK1), with the K_i of 37.9 nM for VRK1 and IC₅₀s of 17 nM and 15 nM for δ and ε isoforms of CK1, respectively.

HY-145940

BAY-204	Inhibitor	99.94%
BAY-204 is an inhibitor of Casein kinase 1 alpha and delta (CSNK1α and δ) useful for the research of proliferative disorders.

HY-120084

BTX161	Inhibitor	99.20%
BTX161, a thalidomide analog, is an effective CKIα degrader. BTX161 mediates human AML cell CKIα degradation more effectively than lenalidomide and activates the DNA damage response (DDR) and p53, while stabilizing p53 antagonist MDM2.

HY-148491

CSNK1-IN-2	Inhibitor	99.22%
CSNK1-IN-2 is a CSNK1A1 inhibitor. CSNK1-IN-1 has inhibitory activity for CSNK1A1 kinase with IC₅₀ values of 2.52 μM. CSNK1-IN-2 can be used for the research of proliferative disorders.

HY-114858

Epiblastin A	Inhibitor	99.44%
Epiblastin A is an ATP competitive casein kinase 1 (CK1) inhibitor with IC₅₀s of 8.9, 0.5, and 4.7 µM for CK1α, CK1δ, and CK1 ɛ, respectively. Epiblastin A induces reprogramming of epiblast stem cells into embryonic stem cells by inhibition of CK1.

HY-N3127

Orobol	Inhibitor	99.28%
Orobol is one of the major soy isoflavones and has various pharmacological activities, including anti-skin-aging and anti-obesity effects. Orobol inhibits CK1ε, VEGFR2, MAP4K5, MNK1, MUSK, TOPK, and TNIK (IC₅₀=1.24-4.45 μM). Orobol also inhibits PI3K isoforms (IC₅₀=3.46-5.27 μM for PI3K α/β/γ/K/δ).

HY-157478

CSNK2A-IN-1	Inhibitor	98.46%
CSNK2A-IN-1 (compound 7C) is a selective CSNK2A inhibitor. CSNK2A-IN-1 has antiviral activity and improved selectivity over PIM3.

HY-153905

Casein kinase 1δ-IN-6	Inhibitor	99.93%
Casein kinase 1δ-IN-6 is a potent and selective protein kinase CK-1δ inhibitor with an IC₅₀ of 23 nM. Casein kinase 1δ-IN-6 shows neuroprotective and anti-inflammatory properties both in vitro and in vivo. Casein kinase 1δ-IN-6 is a promising drug candidate and can be used for neurodegenerative diseases research.

HY-111378

Casein Kinase II Inhibitor IV	Inhibitor	≥98.0%
Casein Kinase II Inhibitor IV is a potent, ATP-competitive of casein kinase II inhibitor with an IC₅₀ of 9 nM. Casein Kinase II Inhibitor IV ia also a human keratinocytes (NHEK) differentiation inducer.

HY-148318

CK2α-IN-1	Inhibitor	98.34%
CK2α-IN-1 (compound 2) is a selective CK2α inhibitor (IC₅₀=7.0 µM; K_i=1.6 µM) that exhibits a non-ATP-competitive mode of action. CK2α-IN-1 exhibits good potential for anticancer studies.

HY-148489

CSNK1-IN-1	Inhibitor	99.23%
CSNK1-IN-1 is a CSNK1A1 inhibitor. CSNK1-IN-1 has inhibitory activity for CSNK1A1 kinase with IC₅₀ values of 21 μM. CSNK1-IN-1 can be used for the research of proliferative disorders.

HY-121944

Ricinine	Inhibitor	99.81%
Ricinine exhibits hepatoprotection in CCl4-induced liver damage. Ricinine is also a CK1α inhibitor, and may activate Wnt pathway.

HY-148328

CK2-IN-4	Inhibitor	99.24%
CK2-IN-4 (compound 5) is a protein kinase (CK2) inhibitor (IC₅₀=8.6 µM). CK2-IN-4 has good potential for research in the areas of cancer, viral infections and glomerulonephritis.

HY-111378A

Casein Kinase II Inhibitor IV hydrochloride	Inhibitor
Casein Kinase II Inhibitor IV Hydrochloride is a small-molecule inducer of epidermal keratinocyte differentiation.

HY-50733A

CX-5011	Inhibitor
CX-5011 is a CK2 inhibitor. CX-5011 also induces Rac1 activation. CX-5011 induces apoptosis and induces cancer cell death.

HY-50733

CX-5011 free base	Inhibitor
CX-5011 free base is a potent CK2 inhibitor. CX-5011 free base also is a Rac-1 activator. CX-5011 free base induces methuosis and promotes macropinocytosis. CX-5011 free base induces apoptosis. CX-5011 free base decreases the expression of rpS6 phosphorylation.

Name
Email *

	Sorry, but the email address you supplied was invalid.